Regulatory press release16.09.2024, 20.00Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024
Regulatory press release13.09.2024, 11.00Asarina Pharma applies for the delisting of the company's shares
Regulatory press release21.08.2024, 11.30Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
Regulatory press release22.07.2024, 08.00NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)
Regulatory press release18.07.2024, 17.45ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE
Regulatory press release27.06.2024, 11.33Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Regulatory press release28.05.2024, 22.00Asarina Pharma AB announces new date for the release of Annual Report for 2023
Regulatory press release21.05.2024, 11.50Asarina Pharma AB announces new date for the release of Annual Report for 2023
Regulatory press release30.11.2023, 10.30Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB
Regulatory press release23.08.2023, 08.30Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)
Regulatory press release23.05.2023, 09.02Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
Regulatory press release22.05.2023, 11.15Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Regulatory press release05.05.2023, 13.33Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America
Regulatory press release18.04.2023, 10.39Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
Regulatory press release01.04.2023, 14.20Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome